On the other hand, there are several approaches underway to inhibit AHR activity in tumour settings, with antagonists targeting the putative suppressive effect of AHR on anti-tumour immunity and resistance to immune checkpoint inhibitors (Campesato et al, 2020; Kober et al, 2023; McGovern et al, 2022). Here, AHR is linked to neoplasm.